Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by tissue Doppler imaging in subjects with chronic ischemic heart failure: Results from the Daunia heart failure registry

Clinics

Volumn 66, Issue 5, 2011, Pages 777-784

  Correale, Michele ^a   Brunetti, Natale Daniele ^a   Totaro, Antonio ^a   Montrone, Deodata ^a   Russo, Anna Rita ^a   Fanigliulo, Anna Maria ^a   Ieva, Riccardo ^a   di Biase, Matteo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Chronic heart failure; Echocardiography; Inflammation; Statins; Tissue doppler imaging

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; BLOOD; CHRONIC DISEASE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; CYTOKINES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROGNOSIS; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 79960785388     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000500012     Document Type: Article

References (33)

1. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010;15:543-62, doi: 10.1007/s10741-010-9168-4.
2. Pai RG, Gill KS. Amplitudes, durations and timings of apically directed left ventricular myocardial velocities: I. Their normal pattern and coupling to ventricular filling and ejection. J Am Soc Echocardiogr. 1998;11:105-11, doi: 10.1016/S0894-7317(98)70067-7.
3. Reant P, Dijos M, Donal E, Mignot A, Ritter P, Bordachar P, et al. Systolic time intervals as simple echocardiographic parameters of left ventricular systolic performance: correlation with ejection fraction and longitudinal two-dimensional strain. Eur J Echocardiogr. 2010;11:834-44 doi: 10.1093/ejechocard/jeq084.
4. Cheng HM, Chuang SY, Hsu PF, Chou P, Chen CH. Systolic time intervals revisited: correlations with N-terminal pro-brain natriuretic peptide in a community population. Heart Vessels. 2005;20:256-63 doi: 10.1007/s00380-005-0844-6.
5. Dilaveris P, Giannopoulos G, Riga M, Synetos A, Stefanadis C. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol. 2007;5:227-37 doi: 10.2174/157016107781024091.
6. Levy WC. Observational studies of statins in systolic heart failure. Heart Fail Clin. 2008;4:201-8 doi: 10.1016/j.hfc.2008.01.006.
7. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839-43 doi: 10.1161/01.CIR.0000084539.58092.DE.
8. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit. 2009;15: MS12-MS23.
9. Krum H, Latini R, Maggioni AP, Anand I, Masson S, Carretta E, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 2007;119:48-53 doi: 10.1016/j.ijcard.2006.07.106.
10. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115:576-83 doi: 10.1161/CIRCULATIONAHA.106.625574.
11. Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007;8:3061-8 doi: 10.1517/14656566.8.17.3061.
12. Yu CM, Chau E, Sanderson JE, Fan K, Tang MO, Fung WH, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002;105:438-45 doi: 10.1161/hc0402.102623.
13. Kishi T, Yamada A, Okamatsu S, Sunagawa K. Atorvastatin might improve ventricular electrostability and decelerate the deterioration of renal function in patients with heart failure and diabetes mellitus. J Cardiol. 2009;53:341-8 doi: 10.1016/j.jjcc.2008.12.002.
14. Aronson D, Mutlak D, Lessick J, Kapeliovich M, Dabbah S, Markiewicz W, et al. Relation of statin therapy to risk of heart failure after acute myocardial infarction. Am J Cardiol. 2008;102:1706-10 doi: 10.1016/j.amjcard.2008.07.057.
15. Huan Loh P, Windram JD, Tin L, Reddy P, Velavan P, Rigby AS, et al. The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. Am Heart J. 2007;153:537-44 doi: 10.1016/j.ahj.2007.01.029.
16. Sankaranarayanan R, Maini S, James MA, Burtchaell S, Chatterjee AK. Do statins improve heart failure outcome in post-myocardial infarction patients with moderate to severe left ventricular dysfunction? Congest Heart Fail. 2010;16:181-6 doi: 10.1111/j.17517133.2010.00165.x.
17. Dickinson MG, Ip JH, Olshansky B, Hellkamp AS, Anderson J, Poole JE, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007;153:573-8 doi: 10.1016/j.ahj.2007.02.002.
18. Das MK, Zipes DP. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention. J Cardiovasc Pharmacol. 2010;55:438-49.
19. Qie L, Meng X, Wang Y, Feng M, Zhong M, Li L. Assessment of regional systolic and diastolic functions affected by atorvastatin in coronary artery disease using tissue Doppler imaging. Clin Cardiol. 2008;31:551-5 doi: 10.1002/clc.20287.
20. Jarnert C, Mejhert M, Ring M, Persson H, Edner M. Doppler tissue imaging in congestive heart failure patients due to diastolic or systolic dysfunction: a comparison with Doppler echocardiography and the atrio-ventricular plane displacement technique. Eur J Heart Fail. 2000;2:151-60 doi: 10.1016/S1388-9842(00)00075-1.
21. Wassmann S, Laufs U, Baumer AT, Müller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-54.
22. Wang CY, Liao JK. Current advances in statin treatment: from molecular mechanisms to clinical practice. Arch Med Sci. 2007;3:S91-S96.
23. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J Sa ́nchez-Pascuala R, Herna ́ndez G, Di ́az C, Lamas S. Effects of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-9 doi: 10.1172/JCI1500.
24. Saijonmaa O, Nyman T, Stewen P, Fyhrquist F. Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol, 2004;286:H2096-102 doi: 10.1152/ajpheart.00894.2003.
25. Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007;8:3061-8 doi: 10.1517/14656566.8.17.3061.
26. Castro PF, Miranda R, Verdejo HE, Greig D, Gabrielli LA, Alcaino H, et al. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J Heart Lung Transplant. 2008;27:435-41 doi: 10.1016/j.healun.2008.01.012.
27. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit. 2009;15:MS12-MS23.
28. Stumpf C, Petzi S, Seybold K, Wasmeier G, Arnold M, Raaz D, et al. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin Sci. 2009;116:45-52 doi: 10.1042/CS20080042.
29. Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS. Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. Isr Med Assoc J. 2010;12:158-62.
30. Wang Y, Zhou Y, Meng L, Lu X, Ou N, Li X. Inflammatory mediators in Chinese patients with congestive heart failure. J Clin Pharmacol. 2009;49:591-9 doi: 10.1177/0091270009333265.
31. Parissis JT, Farmakis D, Nikolaou M, Birmpa D, Bistola V, Paraskevaidis I, et al. Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. Eur J Heart Fail. 2009;11:967-72 doi: 10.1093/eurjhf/hfp125.
32. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al. Effects of statin therapy according to plasma high-sensitivity Creactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009;120:2188-96 doi: 10.1161/CIRCULATIONAHA.109.849117.
33. Liu M, Wang F, Wang Y, Jin R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation. Cardiovasc Drugs Ther. 2009;23:369-76 doi: 10.1007/s10557-009-6186-3.